Catalog Advanced Search
Surrogate Endpoints in Primary Sclerosing Cholangitis (PSC)Contains 1 Component(s) Recorded On: 09/12/2017
Webinar hosted by the Cholestatic and Biliary Diseases Special Interest group on September 12, 2017.
This webinar, presented by the Cholestatic and Biliary Diseases SIG, will focus on the complex topic of Surrogate Endpoints in PSC. The webinar will discuss the Natural History of PSC and the resulting difficulty in identifying relevant endpoints for prognostication and for use in clinical trials. Promising candidate endpoints will be specifically addressed based on the latest clinical research.
David Assis (Moderator)
Dr. David Assis is an assistant professor of medicine in the section of Digestive Diseases at Yale University School of Medicine. His research focuses on autoimmune liver diseases including autoimmune hepatitis and primary sclerosing cholangitis, using animal models and translational approaches including early drug development for autoimmune and cholestatic liver diseases. Dr. Assis is a steering committee member of the North American Consortium for Autoimmune Liver Diseases, and is also currently serving as secretary for the Cholestatic and Biliary Diseases SIG of the AASLD.
Christopher L. Bowlus
Dr. Christopher Bowlus obtained his medical degree at St. Louis University and completed his postgraduate training at University of California Davis and Yale University. Dr. Bowlus is Professor of Medicine and Chief of the Division of Gastroenterology and Hepatology at UC Davis. Dr. Bowlus conducts clinical and translational research in autoimmune liver diseases including primary biliary cholangitis and primary sclerosing cholangitis.
Cyriel L. Ponsioen
Dr. Cyriel Ponsioen works as senior staff member at the Department of Gastroenterology & Hepatology at the AMC. The focus of his clinical as well as research activities lies in inflammatory bowel disease (IBD) and primary sclerosing cholangitis (PSC). The former mainly focuses on microbiota research in IBD. As for PSC, he has built up a research line in epidemiology, disease course, and biomarkers, and he leads a research line looking into the relationship between the gut and the biliary tree. Within the international PSC Study Group he is currently co-chair of the Working Group on Natural History and Biomarkers.
John E. Eaton
Dr. John Eaton is a transplant Hepatologist with a clinical and research focus on cholestatic liver diseases with an emphasis on primary sclerosing cholangitis (PSC) and related comorbid conditions. His clinical practice involves seeing a large volume of patients with PSC and PSC complicated by cholangiocarcinoma. Dr. Eaton’s research focus is the conduction of clinical trials and the discovery of novel biomarkers (including magnetic resonance imaging technologies) that can predict disease outcomes.
Fibrosis Regression: Mechanisms and Clinical ConsequencesContains 1 Component(s) Recorded On: 09/11/2017
Webinar hosted by the Liver Fibrosis Special Interest group on September 11, 2017.
For most of the modern era in medicine, cirrhosis has been regarded as an irreversible condition. For most of the modern era in medicine, cirrhosis has been regarded as an irreversible condition. Contrary to this perception, cirrhosis in animal models of liver injury has long been known to be reversible and case reports from decades ago documenting “reversal” of cirrhosis indicated that fibrosis regression was also possible in human liver disease. The availability of effective therapies for liver diseases such as chronic viral hepatitis has made it possible to determine the effects of fibrosis regression on clinical outcomes. This webinar will explore the fundamental cellular mechanisms of fibrosis regression, evaluate the evidence for fibrosis regression in patients who have undergone successful antiviral treatment and examine the impact of fibrosis regression on clinical outcomes.
Kyle Brown (Moderator)
Dr. Kyle Brown is an Associate Professor of Medicine at the University of Iowa. She completed her gastroenterology and hepatology training at the University of Virginia in Charlottesville. After serving as GI-Hepatology Program Director at Iowa for over a decade, she continues to be involved in medical student, resident and fellow education. Her clinical practice at the University and at the Iowa City Veterans Administration Hospital focuses on general hepatology. Her research interests include complications of advanced liver disease with a specific focus on alterations in iron metabolism.
Dr Ramachandran is an MRC Clinician Scientist at the University of Edinburgh and an Honorary Consultant Hepatologist at the Royal Infirmary of Edinburgh. His research interest is in the basic mechanisms of liver fibrosis, in particular the role of the immune system in regulating fibrogenesis and fibrosis regression.
During his PhD, working with Professor John Iredale and Professor Stuart Forbes, Dr Ramachandran identified and characterised a novel macrophage population which orchestrated the resolution of liver fibrosis. He has recently been awarded an MRC Fellowship to further define hepatic macrophage functional heterogeneity in both pre-clinical models and human chronic liver disease.
Dr. Andrés Duarte-Rojo is a clinical investigator at the level of Associate Professor at the University of Arkansas for Medical Sciences (UAMS) in Little Rock. He completed his gastroenterology fellowship at the Instituto Nacional de Ciencias Médicas y Nutrición, in México City, followed by hepatology fellowships at the University of Toronto and Mayo Clinic in Rochester, MN. His academic training includes a Master and a Doctorate in Medical Science from the University of México. His main research interests include clinimetrics in cirrhosis with a focus in noninvasive markers of fibrosis, exercise in end stage liver disease, and clinical outcomes in liver transplantation.
New DAA's and Controversies in HCV: What Clinicians Need to KnowContains 1 Component(s) Recorded On: 09/07/2017
Webinar hosted by the Hepatitis C Special Interest group on September 7, 2017.
Two new HCV meds have been approved over the summer. This webinar is meant to provide an update on how these fit into current practice. We will also cover the ongoing controversy on the risk of HCC with DAA's and the recent Cochrane report on the benefits of HCV therapy.
Paul Y. Kwo (Moderator)
Dr. Kwo is currently Professor of Medicine and Director of Hepatology at the Stanford University where he joined the faculty in November 2016. Prior to joining the faculty at Stanford, he was at Indiana University for 21 years where he served as the Medical Director of Liver Transplantation. He has distinguished himself in the field of chronic Hepatitis C and has a large practice devoted to current and novel therapies for the treatment of Hepatitis C. He has won multiple awards, both at the university, local, and national level.
Andrew J. Muir (Moderator)
Dr. Andrew Muir is a gastroenterologist whose research activities are focused on developing innovative treatments for a variety of liver diseases. Through his work at the Durham Veterans Administration Medical Center, Dr. Muir has participated in the development programs of many of the direct acting antiviral agents that have revolutionized hepatitis C care. He assumed the leadership of the Gastroenterology and Hepatology Research program at DCRI in 2010 and has expanded the research portfolio to include other liver disorders and gastroenterology outcomes. His particular interests include viral hepatitis, primary sclerosing cholangitis, and liver transplantation. He also has a longstanding interest in healthcare disparities.
Dr. Ioannou is an Associate Professor of Medicine at the University of Washington and the Director of Hepatology at the Veterans Affairs Puget Sound Healthcare System. He is also the co-Director of the Hepatitis C Innovation Team for the Veterans Affairs VISN 20. His research interests include understanding the response to antiviral treatment for hepatitis C and the long-term implications of antiviral treatment in large, real-world cohorts of patients.
Robert S. Brown, Jr
Dr. Brown is the Vice Chair of Transitions of Care and Clinical Chief of the Division of Gastroenterology and Hepatology, as well as a Gladys and Roland Harriman Professor of Medicine, at Weill Cornell Medical College in New York City. His research focuses on the clinical and cost outcomes of liver disease, in particular, viral hepatitis and liver transplantation, using randomized clinical trials, multivariate linear and logistic regression, survival analysis, and decision tree and cost-effectiveness analyses. Several of his liver transplantation studies were funded by the National Institute of Diabetes and Digestive and Kidney Diseases, as well as the pharmaceutical industry, including several multicenter studies to investigate antiviral prophylaxis strategies and various immunosuppressive agents following liver transplantation. Dr. Brown received the Young Investigator Award from the American Society of Transplant Physicians early in his career, in 1996. In 2009, he was honored with the Senior Attending Teaching Award.
Doris B. Strader
Frailty the “Sixth Vital Sign” in Cirrhosis - How Do We Diagnose It and What Can We Do When We Find It?Contains 1 Component(s) Recorded On: 08/31/2017
Webinar hosted by the Acute on Chronic Liver Failure Special Interest group on August 31, 2017.
Frailty is a critical determinant of outcomes in patients with cirrhosis. In this webinar we will present practical methods to assess and quantify frailty in both the outpatient and inpatient clinical settings. We will also provide recommendations on specific interventions once frailty is identified.
Jody Olson (Moderator)
Dr. Jody Olson is currently an Assistant Professor in the departments of Internal Medicine and Surgery at the University of Kansas Medical Center and is primarily affiliated with the liver transplant program. His clinical interests are centered on caring for patients with advanced liver disease in the inpatient and intensive care setting. His research is focused on the critically ill liver disease patient, both acute and chronic and works in the area of acute-on-chronic liver failure. In addition, he is the site primary investigator for the NIH sponsored United States Acute Liver Failure Study Group at the University of Kansas.
Jennifer C. Lai
Dr. Lai is a transplant hepatologist, on faculty at the University of California, San Francisco. Her long-term mission is to help patients with end-stage liver disease survive to and thrive after liver transplantation. Her primary research focuses on integrating core geriatric principles, such as frailty and physical function, into the day-to-day practice of hepatology and transplant medicine to improve the care of her patients. She is the founder and principal investigator of the Functional Assessment in Liver Transplantation (FrAILT) Study, a multi-center collaboration aimed at investigating the impact of frailty on liver transplant outcomes. For her work, she has been named a Beeson Scholar in Aging Research by the National Institute on Aging and a Top 40 Under 40 Leader by the San Francisco Business Times.
Dr. Tandon is an Associate Professor of Medicine, Director of the Cirrhosis Care Clinic and Transplant Hepatologist at the University of Alberta in Edmonton, Alberta, Canada. She completed her Gastroenterology and Hepatology training at the University of Alberta with fellowships at Yale University and the Hospital Clinic in Barcelona. Her clinical practice and research are focused on cirrhosis. Research interests include acute on chronic liver failure and its related complications, sarcopenia, frailty, nutrition, exercise therapy and the early integration of palliative care principles in cirrhosis.
2017 Emerging Trends Conference: Emerging Trends in Non-Alcoholic Fatty Liver DiseaseContains 35 Component(s) Recorded On: 03/19/2017
This course spearheads a development strategy to disseminate new knowledge and treatment options in NAFLD.
The 2017 Emerging Trends Conference will spearhead a development strategy to disseminate new knowledge and treatment options in NAFLD. Major advances in the epidemiology, natural history, pathogenesis and diagnostic modalities have been uncovered although no established treatment has been approved. By facilitating new and exciting translational and therapeutic research in NAFLD, collaborations among clinicians, industry, academic institutions, and public health agencies will be well equipped to deal with this epidemic that threatens our quality of life.
Zobair M. Younossi
Keith D. Lindor
Mary E. McCarthy Rinella
Controversy Regarding HCV Treatment and HCC RecurrenceContains 1 Component(s) Recorded On: 03/08/2017
Webinar hosted by the Hepatobiliary Neoplasia Special Interest group on March 8, 2017.
This webinar will review this latest controversy regarding the increased risk of hepatocellular carcinoma recurrence in patients receiving direct acting antiviral agents for the treatment of HCV. Recent studies have suggested that HCC recurrence is increased in HCV patients receiving direct antiviral agents.
Michael D. Leise (Moderator)
Dr. Leise finished his internal medicine residency, chief residency, Gastroenterology and Transplant Hepatology fellowships at Mayo Clinic, Rochester. He is an Assistant Professor of Medicine with research interests in Hepatitis C, hepatic encephalopathy, and liver transplant outcomes.
Amit G. Singal
Dr. Singal completed his GI and transplant hepatology fellowships at the University of Michigan and is currently an Associate Professor of Medicine at UT Southwestern Medical Center in Dallas. He serves as Clinical Chief of Hepatology and Medical Director of the UT Southwestern and Parkland Memorial Liver Tumor programs. He has over 75 peer-reviewed publications, with the majority examining the hepatocellular carcinoma screening process, from risk assessment to early detection to treatment.
Portal Vein Thrombosis in Cirrhosis: Causes and ConsequencesContains 1 Component(s) Recorded On: 02/28/2017
Webinar hosted by the Portal Hypertension Special Interest group on February 28, 2017.
This webinar will focus on the concept of coagulation in cirrhosis; pathophysiology, concept of a rebalanced coagulation state in cirrhosis and the consequences such as portal vein thrombosis. The management of PVT will be discussed.
Andres Cardenas (Moderator)
Dr. Andrés Cárdenas is currently a Consultant and Clinical Professor of the Institute of Digestive Diseases and Metabolism at Hospital Clinic and University of Barcelona. During his residency in Internal Medicine at Boston University Medical Center, he became interested in advanced liver disease, further pursuing a Research Fellowship in Hepatology for 2 years at Hospital Clinic and University of Barcelona in Spain. He returned to Harvard Medical School and BIDMC for his Clinical Fellowship in Gastroenterology and Hepatology. Dr. Cárdenas is Board Certified in Internal Medicine, Gastroenterology and Hepatology by the American Board of Internal Medicine. His main expertise and research interests are complications of cirrhosis, interventional procedures in patients with cirrhosis and portal hypertension and biliary complications in liver transplant recipients.
Cristina Ripoll (Moderator)
Dr. Cristina Ripoll is currently an attending physician in the gastroenterology division of the internal medicine I department of the Martin- Luther University Halle Wittenberg, Germany. She did her GI and hepatology and transplant training in the Gregorio Marañón Hospital in Madrid, Spain. She did a post-doctoral fellowship at Yale University with Prof. Groszmann and Prof. Garcia-Tsao. Her main research interests are complications of cirrhosis and portal hypertension. She is currently the secretary of the portal hypertension SIG.
Stephen H. Caldwell
Dr. Stephen Caldwell is a hepatologist specializing in a nonalcoholic steatohepatitis (NASH), including its relationship to so-called cryptogenic cirrhosis, ethnic and familial relationships and the role of mitochondrial dysfunction in the disease. He and his colleagues pioneered work on cellular ballooning and the role of small fat droplets in NASH and have also worked extensively with cyanoacrylates in the treatment of gastric variceal bleeding. He is overseeing a number of treatment trials for NASH and related liver fibrosis and is closely involved with a network of physicians and scientists working with coagulation disorders in liver disease. In 1992, he joined the faculty at UVA, helping to develop the hepatology program. Now a professor of medicine in the Division of Gastroenterology and Hepatology at UVA, Dr. Caldwell is board-certified in internal medicine and gastroenterology.
Juan C. Garcia-Pagan
Juan Carlos Garcia-Pagán is a Senior consultant in Hepatology and Head of the Hepatic Hemodynamic section at the Hospital Clinic in Barcelona, Spain and Associate Professor at the University of Barcelona.
He is currently sharing its clinical activity in the hospital with its clinical and basic research at the Institut de Investigacións Biomediques August Pi i Sunyer (IDIBAPS) and is also member of the Centro para Investigación Biomédica en Red de enfermedades hepaticas y digestivas (CIBEREHD). The main research of Interest are: Pathophysiology and treatment of portal hypertension in cirrhosis and of vascular disorders of the liver. He is currently the chair of the EASL-VALDIG (Vascular liver disease group) .
Leon Schiff State-of-the-Art Lecture: Elimination of Hepatitis B: Is it possible?Contains 1 Component(s) Recorded On: 11/15/2016
AASLD's Leon Schiff State-of-the-Art Lecture presented at The Liver Meeting® 2016.
This lecture will provide a vision for the global elimination of hepatitis B (HBV) and strategies to reach that goal by examining the burden of hepatitis B infection and the disparity in prevalence across different parts of the world. Programs preventing hepatitis B infection, available treatment options in chronic hepatitis B, their limitations and novel therapies will also be discussed.
Anna S. Lok
AASLD-APASL Symposium: Portal HypertensionContains 5 Component(s) Recorded On: 11/14/2016
AASLD's AASLD-APASL Symposium presented at The Liver Meeting® 2016.
The symposium will provide a broad overview on the diversity of portal hypertension in the Western World and in the Asia Pacific Region. Experts will discuss the presentation, diagnosis, and management of the consequences of portal hypertension, and will benefit all health care professionals engaged in encountering these patients in their clinical practice.
K. Rajender Reddy
Shiv K. Sarin
Dr. Heller is a senior clinical investigator at the National Institutes of Health where he heads the Translational Hepatology Section. His research focuses on liver disease progression with a particular focus on non-cirrhotic portal hypertension as a model for all patients with portal hypertension. He is focused on enhancing the clinical care of patients with portal hypertension while elucidating mechanisms that underlie the development of portal hypertension due to any etiology. His research encompasses translational and clinical techniques with the ultimate aim of ensuring superb outcomes for patients with liver disease.
2016 Advances for PractitionersContains 3 Component(s) Recorded On: 11/14/2016
AASLD's Advances for Practitioners presented at The Liver Meeting® 2016.
This program will provide trainees and practitioners with a careful review of highly impactful and clinically relevant papers in the management of alcoholic liver disease and NAFLD. Learn the caveats associated with the design, application and final message of key clinical studies, and identify the areas of that need further study. A special focus on emerging trends in the field and how these may impact the clinical management of alcoholic liver disease and BAFLD in coming years will be discussed.
Brent A. Tetri
Christopher P. Day